The Effect of Corticosteroid Treatment on Pulmonary Function in Sarcoidosis

Smellie, Hugh; Apthorp, G. H.; Marshall, Robert J.

doi:10.1136/thx.16.1.87

Cited by 25 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…About a quarter of our patients taking corticosteroids who had dyspnoea were relieved. The relief was never dramatic, nor was it related either to the degree of radiographic improvement or to improvement in lung function (Smellie et al, 1961). Grievous dyspnoea has been proposed as an indication for using corticosteroids (American Thoracic Society, 1960;Scadding, 1961), but we are convinced that this is worth while only in so-called alveolar capillary block due to acute sarcoidosis as seen chiefly in North America.…”

Section: Discussionmentioning

confidence: 94%

“…The results of lung function studies in some of these patients have already been reported (Marshall, Smellie, Baylis, Hoyle, and Bates, 1958;Smellie et al, 1961;Hamer, 1963). RELAPSE ON WITHDRAWAL OF TREATMENT When treatment was stopped or reduced excessively, 34 of 47 patients showed radiographic evidence of subsequent relapse.…”

Section: Effect Of Corticosteroids On Dyspnoeamentioning

confidence: 85%

“…Dyspnoea was measured before and after treatment by grades already described (Smellie, Apthorp, and Marshall, 1961). The 52 treated patients were observed for a mean duration of 10-5 years (range 2 to 25 years).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Prolonged treatment of pulmonary sarcoidosis with corticosteroids

Hoyle

Smyllie

Leak

1967

Thorax

View full text Add to dashboard Cite

The results are described of prolonged corticosteroid treatment in 52 patients with pulmonary sarcoidosis observed for a mean duration of 10-5 years from diagnosis. Twenty of the patients -were treated for less than one year, the remainder for a mean of five years. The mean length of observation after discontinuing treatment was 5*5 years. Selection of patients for treatment was based on (1) evidence from radiographic observation, even for two years or more, that the disease was progressive so that spontaneous remission was improbable; and (2) evidence of disturbed lung function, especially the onset of dyspnoea or an impaired diffusing capacity. Treatment, conveniently with prednisone at a maintenance dose of about 15 mg. daily, should be continued for at least a year and often for much longer until withdrawal is not followed by radiographic relapse. Such treatmnent does not increase the chance of a complete remission even when given at an early stage of the disease; and relief of dyspnoea is unpredictable and seldom considerable. But prolonged treatment will halt progressive lung destruction and appears to curb the eventual mortality.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Effect Of Corticosteroids On Dyspnoeamentioning

confidence: 85%

See 1 more Smart Citation

Prolonged treatment of pulmonary sarcoidosis with corticosteroids

Hoyle

Smyllie

Leak

1967

Thorax

View full text Add to dashboard Cite

show abstract

“…Von anderen Autoren wurden während Therapie Anstiege [10,17] und Reduktionen [17] der Compliance beschrieben. Es handelte sich um kleine Untersuchungszahlen, wobei zwischen Granulomatosen und Fibrosen nicht optimal unterschieden wurde.…”

Section: Das Verhältnis Des Residual Volumens Zur Totalkapazität War unclassified

Atemmechanik und Kortikosteroidtherapie bei der Lungensarkoidose

Doll¹,

Wagner²,

Kröpelin³

1973

Respiration

View full text Add to dashboard Cite

In 41 patients with a lung sarcoidosis the effect of corticosteroids on mechanics of breathing was examined. As a rule the compliance is already normal prior to the therapy in patients with granulomatosis, it is not affected by the therapy. Fibroses cause an irreversible compliance reduction. In very few cases the resistance is affected by proliferations, whereas in case of extensive fibroses clear increases can be measured. In these cases a corticoid therapy can reduce the resistance if it was increased by a secondary bronchitis

show abstract

“…The clinical course of pulmonary sarcoi dosis and its response to therapy has been described by investigators usually in terms of roentgenographic findings [8,17] or pul monary function abnormalities [1,3,4,10,12,[18][19]20]. Only a few authors have re lated the clinical or functional findings to structural changes.…”

Section: Introductionmentioning

confidence: 99%

Pulmonary Sarcoidosis

Ct¹,

Ae²,

Rosen³

et al. 1979

Respiration

View full text Add to dashboard Cite

Discrepancies were observed between functional (PFT), chest roentgenographic, and open lung biopsy findings (granulomata, interstitial pneumonitis, angiitis, and fibrosis) in 81 patients with clinical diagnosis of sarcoidosis. A combination of normal PFT and Type 1 roentgenographic findings (hilar lymphadenopathy) was associated with minimal lung lesions without fibrosis. Type 1 findings alone did not preclude extensive lesions or fibrosis. Advanced roentgenographic and PFT abnormalities correlated with the presence of extensive lung lesions. The pulmonary diffusing capacity correlated best with specific and overall lung pathology, and roentgenographic types. Only this test differentiated the extent of granulomata and the roentgenographic types. Moderate degrees of other pathologic changes were not distinguished by any other PFT. Degrees of overall lung pathology correlated with an individual PFT and most significantly with overall PFT (p < 0.001). Serial studies of PFT are a practical and valuable means for assessment of the disease process in sarcoidosis.

show abstract

The Effect of Corticosteroid Treatment on Pulmonary Function in Sarcoidosis

Cited by 25 publications

References 6 publications

Prolonged treatment of pulmonary sarcoidosis with corticosteroids

Prolonged treatment of pulmonary sarcoidosis with corticosteroids

Atemmechanik und Kortikosteroidtherapie bei der Lungensarkoidose

Pulmonary Sarcoidosis

Contact Info

Product

Resources

About